We have become aware of an individual who is falsely representing themselves as a member of the Celerion HR team. Please be cautious when responding to any communication that purports to come from Celerion. All email communication from Celerion will come from an email address appended @celerion.com. No other addresses are legitimate. #hr
Celerion
Pharmaceutical Manufacturing
Lincoln, NE 15,321 followers
Celerion Can Take You from First-In-Human through Proof-of-Concept.
About us
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. Our operations are strategically located in: Lincoln, Nebraska (Corporate Headquarters) Philadelphia, Pennsylvania Phoenix, Arizona Belfast, Northern Ireland,UK Zurich, Switzerland Vienna, Austria Richmond, Virginia Montreal, Quebec, Canada For more information, visit: www.celerion.com
- Website
-
http://www.celerion.com
External link for Celerion
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Lincoln, NE
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Applied Translational Medicine, Global Clinical Research (Phase I and II, NDA-enabling clinical pharmacology), Data Management and Biometrics, Global Bioanalytical Services (discovery through late phase), Drug Development Services, and Global Clinical Development
Locations
Employees at Celerion
Updates
-
As an industry, we need to develop treatments to reverse the effects, slow progression, and even eliminate this degenerative disease. Optimized early-phase study designs can be leveraged for therapies indicated for Alzheimer’s Disease and Dementia to accelerate drug development. Design elements such as cerebral spinal fluid (CSF) collection in healthy volunteers for robust PK assessment, exploration in a cohort of older adults, and cognitive testing can provide early signals of efficacy to support patient trials. Learn how ‘Adaptive and Innovative Study Designs to Accelerate Drug Development from First-in-Human to First-in-Patient’: https://lnkd.in/dKVxHsmm #WorldAlzheimersMonth #EarlyClinicalResearch
-
-
Happy Labor Day from Celerion! Today, we honor the dedication and hard work of all our team members who contribute to the advancements in clinical research. Your commitment to improving health and well-being is truly inspiring. At Celerion, every day is a testament to the power of collaboration, innovation, and relentless pursuit of knowledge. Your efforts are shaping the future of medicine, making a real difference in the lives of patients worldwide. Let's take a moment to celebrate the incredible progress we've made and look forward to the exciting breakthroughs ahead. Thank you for your passion and perseverance. Together, we are paving the way for a healthier tomorrow. Learn more about Celerion: https://celerion.com #LaborDay #ClinicalResearch #HealthcareHeroes #InnovationInHealth
-
-
September is Self-Care Awareness Month! At Celerion, we understand that caring for yourself is just as important as caring for others. As we strive to advance clinical research and improve global health, we also recognize the vital role of self-care in our daily lives. This month, let's commit to prioritizing our well-being. Whether it's taking a break, practicing mindfulness, getting enough sleep, or enjoying a healthy meal, every small step counts. Remember, self-care isn't selfish—it's essential. By caring for ourselves, we can better support our mission to improve health outcomes for everyone. Take a moment today to do something kind for yourself. You've earned it! 🌿💖 Learn more about Celerion: https://celerion.com #SelfCareAwarenessMonth #Celerion #ClinicalResearch #Wellbeing #HealthFirst #TakeCareOfYou
-
-
LC/MS/MS is a mature technology in Bioanalysis and is often called a commodity. This may be true as it is available in many laboratories around the world. However, with today’s complex new modalities, highly challenging small molecules, peptides, and oligonucleotides, the challenges in developing LC/MS/MS assays are greater than ever. At Celerion, we’ve been doing LC/MS/MS analysis in our laboratories since 1992. We have a long history of innovations and experience with challenging projects. For instance, we have performed bioanalysis of peptides and oligonucleotides for over 20 years. The complex small molecules such as protein degraders and biomarkers often require close collaboration with our on-site clinics for proper sample collection or our LBA and Flow Cytometry teams for associated biomarker analysis. In the case of ADC’s you get all of your complex bioanalysis under one roof with one set of management. Even the traditional small molecules are smaller, stickier, less stable, and nonpolar. All challenges that a lab with experience must address. Learn more about Celerion's Bioanalytical Services: https://lnkd.in/e94Jchx #Bioanalysis #LCMSMS #Peptides #Oligonucleotides #SmallMolecules #DrugDevelopment #PharmaResearch
-
-
Join us on September 13th as Michael Gröschl, Technical Director of Automation & CSV at Celerion Switzerland, presents "A fully automated ELISA for determining serotype-specific IgG against Streptococcus pneumoniae capsular polysaccharides" at the EBF Autumn Focus Workshop 2024 in Malaga, Spain. Learn more about this event: https://lnkd.in/djsMt9nr #EBF2024 #VaccineAssays #Automation #Bioanalytics
-
-
Join us at Celerion's "Drug-Drug Interaction Happy Hour: Best Practices for Cocktail Studies" Presentation & Dinner on October 10 in Cary, NC. Insights from experts Chad Briscoe, Ph.D., and Aernout van Haarst, Ph.D., cocktails & networking. RSVP by September 26: [email protected] (limited to professionals in biotech/pharma companies) #DrugInteraction #Pharmacology #NetworkingEvent #Celerion
-
Once a study is awarded, we can be ready in a matter of weeks to start participant dosing. We built efficiencies into our start-up processes, have the capacity to conduct multiple ADME studies at once and have the expertise to execute them. Our dedicated team of ADME specialists, including our on-site Nuclear Pharmacist, have conducted more than 100 radiolabeled clinical studies. Read more: https://lnkd.in/e8Hk8bdE #ADMEExperts #ClinicalStudies #MultiStudyCapacity #ClinicalInnovation
-
-
We’re thrilled to announce an interview with Johannes Stanta, Global Director of Molecular and Cell Biology at Celerion, on Detecting Exposure Risk from Gene Therapy Viral Vectors. Dr. Stanta and his team have been making groundbreaking strides in the field of gene therapy. After uncovering concerns about the reliability of data generated by most labs, they developed a new, streamlined approach for shedding assays specifically tailored for adeno-associated virus (AAV) vectors. AAV vectors are currently the most popular in gene therapies, and this innovative method ensures more accurate detection of exposure risks. Check out the interview now for insights into how these advancements are shaping the future of gene therapy: https://lnkd.in/emvh--HF #GeneTherapy #Innovation #AAVVectors #ScienceBreakthrough #MolecularBiology
-
-
Celerion’s site network is one of the largest for organ insufficiency PK studies. Across the US and EU, we have access to patients and specialist principal investigators with expertise in renal and hepatic impairment PK studies for budget-friendly solutions. Learn more -> https://lnkd.in/dMe-77ym #PKStudiesNetwork #RenalHepaticExpertise #GlobalPatientAccess #ClinicalTrialExcellence
-